Overview

A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-06-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and toxicity of irinotecan with dabrafenib, cetuximab/panitumumab in the second line of treatment for the potential treatment of colorectal cancer that: has a metastatic, inoperable; has a mutation in the BRAF gene. Participants in this study will receive one of the following study treatments: These participants will receive in the second line is irinotecan, dabrafenib + trametinib, cetuximab or panitumumab. This trial is currently enrolling participants who will receive either irinotecan and dabrafenib plus cetuximab or panitumumab in the second line of therapy. The study team will monitor how each participant responds to the study treatment for up to about 3 years.

Phase:

PHASE2

Details

Lead Sponsor:

Blokhin's Russian Cancer Research Center

Collaborators:

City Clinical Oncology Hospital No 1
MMCC Kommunarka MHD
Moscow City Oncology Hospital No. 62
The Loginov MCSC MHD